Anti-GITR antibodies - Bristol-Myers SquibbAlternative Names: Anti-AITR antibody; Anti-CD357 antibody; Anti-GITR-D antibody; Anti-TNFRSF18 antibody
Latest Information Update: 03 Mar 2016
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Glucocorticoid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 26 Feb 2016 Phase-I clinical trials in Cancer in USA (unspecified route) (Bristol-Myers Squibb website, March 2016)
- 05 Jan 2016 Bristol-Myers Squibb has patent protection for Anti-GITR antibodies in USA